Agnese

All the posts published.
The latest data points to a 71% response rate to the drug
Chairman John Clarkson said: “In what has been a challenging year for ProAxsis, positive management actions have helped transform the company’s outlook"
The City broker pointed to the last fair value calculation for the assets held by the investment company, which specialises in life sciences and…
It is envisaged that the validation and initial commercialisation can be achieved largely from ProAxsis' existing resources
“The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients"
"This placement provides further impetus behind our model of 'capital-light' investment combined with pro-active management and value-added support to our portfolio," said…
NetScientific currently has a 5.7% stake in PDS Biotechnology, which is at the cutting edge of immuno-oncology
WHI Ireland has a sum-of-the-parts valuation for the shares of 162p - a 40% premium to the current price
NetScientific plc ("NetScientific", the "Group" or the "Company")   NetScientific participates in PDS Biotechnology $45m equity issue and related party transaction London,…
NetScientific plc ("NetScientific", the "Group" or the "Company")   PDS Biotech Announces Proposed Offering of Common Stock   London, UK – 15…
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR…
THE INFORMATION IN THIS ANNOUNCEMENT, WHICH INCLUDES CERTAIN INFORMATION DRAWN FROM PUBLIC SOURCES, DOES NOT PURPORT TO BE COMPREHENSIVE AND HAS NOT…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical…
NetScientific plc ("NetScientific" or the "Group") ProAxsis Update ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test  London, UK –…
NetScientific plc ("NetScientific", the “Group” or the "Company") Result of AGM   London, UK – 3 June 2021 – NetScientific plc (AIM: NSCI),…
TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to…
TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to…
NetScientific plc ("NetScientific" or the "Group") ProAxsis Update Following transformative year ProAxsis focuses on delivering revenues and profitability London, UK – 24…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study…
NetScientific plc ("NetScientific", the "Group" or the "Company") EMV Capital advises on £3.4m funding for smart sensor maker PointGrab   London, UK…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results   London,…
NetScientific plc ("NetScientific", the "Group" or the "Company")   EMV Capital advised on £2.9m funding for anaesthetic gas recycling tech business SageTech…
NetScientific plc ("NetScientific", the "Group" or the "Company") PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at…
NetScientific plc ("NetScientific", the “Group” or the "Company") EMV Capital advised on £740k oversubscribed funding round for 5G and satellite phased array…
 NetScientific plc (“NetScientific” or the “Company”) Notice of AGM and Annual Report & Accounts     London, UK – 14 April 2021…
NetScientific plc ("NetScientific", “NSCI”, the Group” or the "Company") Preliminary Results for the year ended 31 December 2020 Company poised for further…
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS Biotechnology Reports Final Results for the Full Year 2020 & Business Update  …
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS COVID-19 Vaccine Commercialisation Update c. $60m Funding Commitment by Brazilian government for Clinical…
NetScientific plc ("NetScientific", the “Group” or the "Company")   PDS COVID-19 Vaccine Commercialisation Update   Blanver joins PDS-Farmacore COVID-19 Vaccine Consortium  …
NetScientific plc ("NetScientific" or the "Company") ProAxsis Update London, UK – 22 February 2021 – NetScientific plc (AIM: NSCI), the life sciences and…
NetScientific plc ("NetScientific" or the "Company")   PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by…
NetScientific plc ("NetScientific" or the "Company") Suspension of Trading on AIM NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation…
NetScientific plc ("NetScientific" or the "Company") Issue of Shares, Director/PDMR Shareholding and Total Voting Rights  NetScientific plc (AIM: NSCI), the life sciences,…
TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to…
NetScientific plc ("NetScientific" or the "Company") PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19…
NetScientific plc ("NetScientific" or the "Company") ProAxsis Limited awarded Innovate UK grant to utilise company technology to identify high risk COVID-19 patients…
NetScientific plc (“NetScientific”, the “Group” or the “Company”) Board changes and grant of Options   London, UK – 2 December 2020 –…
NetScientific plc (“NetScientific” or the “Company”)   NetScientific’s EMV Capital Ltd leads a £1.28m pre-Series A round in SageTech Medical Equipment Ltd…
NetScientific plc ("NetScientific" or the "Company") ProAxsis Limited appoints DiaPharma as distributor to key North America region London, UK – 19 November…
NetScientific plc ("NetScientific" or the "Company") PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine PDS0203 prioritized for clinical…
NetScientific plc ("NetScientific" or the "Company")   PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck…
NetScientific plc ("NetScientific" or the "Company")   NetScientific plc   NetScientific acquires 100% control of portfolio company ProAxsis Limited London, UK – 16 October…
Agnese, Author at NetScientific